Dec 19, 2016 7:00am EST Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
Dec 8, 2016 7:00am EST Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)
Dec 2, 2016 7:21am EST Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Nov 30, 2016 7:00am EST Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference
Nov 10, 2016 7:00am EST Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
Nov 7, 2016 7:00am EST Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
Nov 2, 2016 7:00am EDT Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference
Nov 1, 2016 4:30pm EDT Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
